- Targeted Therapy
- Immunotherapy
- Radiation Therapy
- Neurosurgical Treatments
- Cryoablation
- Radiofrequency ablation
Kidney Cancer Treatment Market was valued at USD 6,132.8 million in 2022 and is anticipated to grow at a CAGR of 6.4 % over 2023-2029. The kidney cancer treatment market refers to the market for developing therapeutics and treatment options specifically targeted at kidney cancer, also known as renal cell carcinoma (RCC). Kidney cancer is a type of cancer that originates in the kidneys, which are responsible for filtering waste from the blood and producing urine. It is a kind of cancer that is rather prevalent, with regional variations in incidence rates. The kidney cancer treatment market encompasses a broad variety of treatment modalities, including surgery, radiation therapy, chemotherapy, immunotherapy, targeted therapy, and combination therapies. These therapies aim to stop or at least limit the proliferation of cancer cells, stop the disease from spreading, and enhance the patient’s quality of life. The kidney cancer treatment market is primarily driven by the increasing incidence and prevalence of kidney cancer worldwide.
According to the World Cancer Research Journal, kidney cancer causes 144,000 deaths and 338,000 new cases worldwide each year. Other factors that support the expansion of the kidney cancer treatment market include improvements in diagnostic procedures like computed tomography (CT) scans and magnetic resonance imaging (MRI), the creation of novel and targeted therapies like tyrosine kinase inhibitors and immune checkpoint inhibitors, and increase in research and development activities. Moreover, development of immunotherapy in kidney cancer treatment, adoption of minimally invasive surgical techniques and biomarker-based diagnosis and treatment crate favourable environment for the growth of the kidney cancer treatment market in the forecasting years. However, expensive kidney cancer treatment, especially when considering the cost of surgeries, targeted therapies, immunotherapies, and follow-up care can limit the access to advanced treatment options for some patients in regions with limited healthcare resources impede the kidney cancer treatment market. Various pharmaceutical companies are introducing innovative treatment options and advancements in medical technology to further contribute to market growth. For instance, in November 2021, Merck’s KEYTRUDA (pembrolizumab) got FDA approval as adjuvant therapy for patients with renal cell carcinoma (RCC) following surgery.
Study Period
Base Year
CAGR
Largest Market
Fastest Growing Market
kidney cancer treatment market is expected to grow at significant rates owing to the factors such as increase in prevalence of kidney cancer due to the lifestyle changes and increase in smoking and consuming alcohol. In addition, increase in geriatric population who are more prone to the kidney related diseases coupled with the increase in R&D support and investments by the government in screening of cancer and in development of new treatment of drugs. Furthermore, availability of kidney cancer treating drugs are low, it is likely to act as growth opportunity for development of new drug treatments for the treatment. However, high prices of available branded drugs for the treatment of kidney cancer and high R&D expenditure for the development of new drugs are expected to hinder the market growth over the forecast period.
The global kidney cancer treatment market was valued at USD 6,132.8 million in 2022
The kidney cancer treatment market key players are Abbott Laboratories, Amgen Inc., Bayer AG, Bristol-Myers Squibb, F. Hoffmann-La Roche, Merck KGaA (EMD Serono), Novartis International AG
In our report, we provide 12-15 market players’ information into the report. However, based on the client’s request we will provide additional country and regional market players information as well.